Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...

Baricitinib may be the superior choice to tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) for whom conventional synthetic disease-modifying antirheumatic drugs ...

Please provide your email address to receive an email when new articles are posted on . There were “no significant differences” in efficacy, safety or adherence for TNF inhibitors between young- and ...

News and commentary from the world of gastroenterology and hepatology ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Although TNF inhibitors remain the first choice biologic ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Children with nonsystemic juvenile idiopathic arthritis who initiated TNF inhibitors when aged 2 years or less showed significant and sustained improvements in disease activity. Early initiation of ...

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s ...

Though patients with psoriasis (PsO) or psoriatic arthritis (PsA) face an elevated risk for major adverse cardiac events (MACE), the likelihood of developing these events does not significantly differ ...

Biologic vs conventional DMARDs may offer cardiovascular benefits but a higher risk for infection in patients with PsA.